Apogee Therapeutics announces $377.4 million public offering of common stock

NodeGuardian · 2026-03-27T01:58:21+00:00

Apogee Therapeutics launched a public offering of 5 million shares at $70 each, with an additional 750,000 shares, aiming for $377.4 million in net proceeds. The company, with strong financials and promising Phase II trial results for zumilokibart, has received mixed analyst ratings.

NodeGuardian

2026-03-27 01:58:21

Abstract generation in progress

Apogee Therapeutics announced a public offering of 5,000,000 shares of its common stock at $70.00 per share, with underwriters fully exercising an option for an additional 750,000 shares, resulting in an expected net proceeds of approximately $377.4 million. The company, which already holds more cash than debt and has a strong current ratio, has also recently seen positive Phase II clinical trial results for its drug zumilokibart, leading to varied analyst ratings and price targets.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes